{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:48:26Z","timestamp":1785466106610,"version":"3.56.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Duke-NUS Oncology Academic Clinical Programme Proton Research Fund"},{"name":"Ferring"},{"name":"AstraZeneca"},{"name":"Varian"},{"name":"Sanofi"},{"name":"GenomeDx Biosciences"},{"name":"Medlever"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ijrobp.2019.02.043","type":"journal-article","created":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T21:04:24Z","timestamp":1556744664000},"page":"362-364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Circulating Tumor DNA to Personalize Treatment in Nasopharynx Cancer \u2013 Time to Look \u201cAhead\u201d?"],"prefix":"10.1016","volume":"104","author":[{"given":"Melvin L.K.","family":"Chua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2019.02.043_bib1","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0140-6736(15)00055-0","article-title":"Nasopharyngeal carcinoma","volume":"387","author":"Chua","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2019.02.043_bib2","article-title":"Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: A randomized controlled trial","author":"Chan","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.02.043_bib3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijrobp.2019.01.007","article-title":"Plasma Epstein-Barr virus DNA load after induction chemotherapy predicts outcome in locoregionally advanced nasopharyngeal carcinoma","volume":"104","author":"Huang","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.02.043_bib4","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2019.02.043_bib5","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ijrobp.2015.08.003","article-title":"The prognostic value of plasma Epstein-Barr viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma","volume":"93","author":"Liu","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.02.043_bib6","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/annonc\/mdu117","article-title":"Plasma Epstein\u2013Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma","volume":"25","author":"Leung","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2019.02.043_bib7","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1158\/1078-0432.CCR-17-2656","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: Individual patient data pooled analysis of four randomized trials","volume":"24","author":"Chen","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2019.02.043_bib8","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: An international, multicenter study of the Mayo clinic phase 2 consortium (NCI-9742)","volume":"36","author":"Ma","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.02.043_bib9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/cncr.31741","article-title":"Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma","volume":"125","author":"Guo","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2019.02.043_bib10","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/ijc.31856","article-title":"The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification","volume":"144","author":"Lee","year":"2019","journal-title":"Int J Cancer"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301619302871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301619302871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:44:32Z","timestamp":1759743872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301619302871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0360301619302871"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2019.02.043","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating Tumor DNA to Personalize Treatment in Nasopharynx Cancer \u2013 Time to Look \u201cAhead\u201d?","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2019.02.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}